INS316 solution for inhalation + hypertonic saline 3% sodium chloride solution
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Interstitial Lung Disease
Conditions
Interstitial Lung Disease
Trial Timeline
Jan 1, 2003 → Apr 1, 2004
NCT ID
NCT01381666About INS316 solution for inhalation + hypertonic saline 3% sodium chloride solution
INS316 solution for inhalation + hypertonic saline 3% sodium chloride solution is a phase 2 stage product being developed by Merck for Interstitial Lung Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01381666. Target conditions include Interstitial Lung Disease.
What happened to similar drugs?
1 of 5 similar drugs in Interstitial Lung Disease were approved
Approved (1) Terminated (2) Active (3)
✅Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mgJohnson & JohnsonApproved
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01381666 | Phase 2 | Terminated |
Competing Products
20 competing products in Interstitial Lung Disease